No Detail Found!

Development and modification in therapeutic antibodies to combat various diseases

Author(s)
Ghulam Akbar Department of Biochemistry, University of Agriculture, Faisalabad, Pakistan
Muhammad Anjum Zia Department of Biochemistry, University of Agriculture, Faisalabad, Pakistan
Ali Ahmad Department of Agronomy, University of Agriculture, Faisalabad, Pakistan
Sana Ahmad Department of Biochemistry, University of Agriculture, Faisalabad, Pakistan
Aamna Rafique Department of Biochemistry, University of Agriculture, Faisalabad, Pakistan
Neha Arooj Department of Biochemistry, University of Agriculture, Faisalabad, Pakistan
Shahneela Nusrat Department of Biochemistry, University of Agriculture, Faisalabad, Pakistan
Abstract
In 1986, as the initial monoclonal antibody was accepted by the United States Food and Drug Administration (US FDA), and this time antibody engineering has intensely evolved. Among rapidly emerging therapeutic techniques, antibody engineering based treatment is the best one which is being used to cure human disorders. Antibodies are antigen identifying immunoglobulins which have various repertoire domain capable of antigen specificity. This diverse antibody response is more increased by modifications including somatic recombination, hyper-mutation and post-translational modifications like Fc glycosylation may further upsurge the diversity of effector functions. However, variations in glycan structures effectively helps to the antibody's functional capabilities. Glycosylation is the modification in protein after the translational process during antibodies synthesis. Glycosylated antibodies play a major role in improving efficiency, pharmacokinetics and safety of curative antibodies. In the pharmacological industries, the regulation and adjustment of therapeutic antibodies is the key point in antibodies engineering. In this review article the recent approaches and novel antibody C-terminals and N-terminals modifications, and their impact on half-life, immunogenicity and effector functions have been discussed. Moreover, the recent progresses in the glycosylation and glycosylation control along with the risk assessments have also been described here.
Publication Details
Page(s) 2097-2110
Published Journal: Pure and Applied Biology, Volume: 9, Issue: 3, Year: 2020

Request the full text from PASTIC

Keywords
Antibody engineering, pharmacokinetics, Therapeutic approaches, glycosylation, improved efficacy
0

Citations

0

Downloads

94

Views